{"classes":[{"categories":[{"measurements":[{"comment":"Too few events have occurred to estimate the upper 95% Confidence Interval.","groupId":"OG000","lowerLimit":"7.8","upperLimit":"NA","value":"9.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented. Duration of response will be analyzed using Kaplan-Meier methods.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group 1 (6/6 UGT1A1 genotype):\\> Patients receive 150 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 100 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 1600 mg/m\\^2/day capecitabine PO BID on days 2-15\\> \\> Group 2 (6/7 UGT1A1 genotype):\\> Patients receive 150 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 85 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 400 mg/m\\^2/day capecitabine PO BID on days 2-15.\\>\n\n\\> Group 3 (7/7 UGT1A1 genotype):\\> Patients receive 75 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 85 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 400 mg/m\\^2/day capecitabine PO BID on days 2-15","id":"OG000","title":"All Patients (6/6, 6/7, 7/7 UGT1A1 Genotype)"}],"paramType":"MEDIAN","populationDescription":"All patients who achieved a CR or PR are included in this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}